MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Erdafitinib

CAS No. : 1346242-81-6

MCE 国际站：Erdafitinib

产品活性：Erdafitinib (JNJ-42756493)是有效的有口服活性的 FGFR 家族抑制剂；抑制FGFR1-4活性的 IC₅₀ 分别为1.2, 2.5, 3.0和5.7 nM。

研究领域：Protein Tyrosine Kinase/RTK  |  Apoptosis

作用靶点：FGFR  |  Apoptosis

In Vitro: Erdafitinib (JNJ-42756493) inhibits the tyrosine kinase activities of FGFR1-4 in time-resolved fluorescence assays with IC₅₀ values of 1.2, 2.5, 3.0 and 5.7 nM, respectively. The closely related VEGFR2 kinase is less potently inhibited (30-fold less potent compared to FGFR1) by erdafitinib, with an IC₅₀ value of 36.8 nM. Erdafitinib binds FGFR1, 3, 4, and 2 with K_d values of 0.24, 1.1, 1.4 and 2.2 nM, respectively. The K_d value for VEGFR2 is higher at 6.6 nM. Erdafitinib inhibits proliferation of FGFR1, 3, and 4 expressing cells with IC₅₀ values of 22.1, 13.2, and 25nM, respectively.

In Vivo: In xenografts from human tumor cell lines or patient-derived tumor tissue with activating FGFR alterations, Erdafitinib administration results in potent and dose-dependent antitumor activity accompanied by pharmacodynamic modulation of phospho-FGFR and phospho-ERK in tumors.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Drug Repurposing Compound Library  |  Reprogramming Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Lung Cancer Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Targeted Therapy Drug Library   |  Angiogenesis-Related Compound Library  |  Anti-Liver Cancer Compound Library   |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Heterocyclic Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Cytokine Inhibitors Library  |  Cell Death Library  |  Multi-Target Compound Library  |  Bioactive Compound Library Max  |  Anti-Fibrosis Compound Library  |  MG-132  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Tamoxifen  |  Y-27632  |  Paclitaxel  |  Z-VAD-FMK  |  LY294002  |  2-Deoxy-D-glucose  |  Angiotensin II human  |  Acetylcysteine  |  Staurosporine  |  Actinomycin D  |  SB-431542  |  5-Fluorouracil  |  Bortezomib  |  Oxaliplatin  |  Deferoxamine mesylate  |  Sorafenib  |  Trametinib  |  Gemcitabine  |  Temozolomide  |  Etoposide  |  Rotenone  |  Mdivi-1  |  Monomethyl auristatin E  |  Decitabine  |  Ruxolitinib  |  Elesclomol  |  DAPT

热门产品线：重组蛋白  |  药物筛选  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。